HOME >> MEDICINE >> NEWS
Immunex Advances CD40 Ligand To Phase II Clinical Trial In People With Metastatic Kidney Cancer

CD40L Moved Forward Based On Outcomes Of Multi-Dose Safety Trial

SEATTLE - Immunex Corporation (Nasdaq: IMNX) announced today that it has launched a Phase II trial of the investigational agent CD40 Ligand (CD40L) in the most common form of kidney cancer, renal cell carcinoma. The company is continuing the development of CD40L based on results of a multi-dose Phase I trial of the drug in advanced cancer patients.

The Phase I study, which evaluated escalating doses of CD40L in patients with recurrent solid tumors and lymphoma, has been completed and the objectives of the study were met. The results of this multi-dose study will be presented at a future medical meeting. Several pre-clinical studies on the anti-tumor effect of CD40L will be presented next week at the 35th Annual Meeting of the American Society of Clinical Oncology (ASCO). In these studies, conducted in both mice and fresh human tumor samples, CD40L inhibited tumor growth in multiple solid tumor types, such as breast, lung, ovarian and colon.

"Based on the results of these safety trials, Immunex is moving forward with a Phase II trial of CD40L in metastatic renal cell carcinoma," said Ann Hayes, M.D., senior vice president, medical development, Immunex. "Patients with this disease currently have limited treatment options. Treatment with CD40L represents a novel approach to treating cancer, by potentially having a direct effect on tumor cells and by stimulating the immune system to recognize and seek out cancer cells for destruction."

The study, being conducted in three cancer treatment centers across the United States, will evaluate the safety and efficacy of the drug in metastatic renal cell carcinoma.

Approximately 30,000 new cases of kidney cancer will be diagnosed this year in the United States and about 11,900 people will die from this disease. It is the 8th most common cancer in men and the 10th most common in women. Ren
'"/>

Contact: Lisa Crisera
criseral@immunex.com
206-389-4346
Immunex Corporation
14-May-1999


Page: 1 2

Related medicine news :

1. Immunex Files Supplemental NDA for NOVANTRONE
2. Immunexs TRAIL Molecule Shows Potential As Anti-Tumor Agent
3. Advances in Uterine Leiomyoma Research: 2nd NIH International Congress
4. Advances in plasma physics at Annual APS Meeting
5. Advances in plasma physics at Annual APS Meeting
6. Advances in understanding brain circuits responsible for tics in Tourettes shed light on disorder
7. Advances in Skeletal Anabolic Agents for the Treatment of Osteoporosis: A scientific meeting
8. Advances emerging in hepatitis management
9. Advances in prevention and treatment research hold promise for pipeline
10. Advances in MRI imaging may lead to new standards for faster diagnosis of multiple sclerosis
11. Peanut Allergy: Major Advances in Treatment and Education

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/19/2019)... ... 19, 2019 , ... NCPDP announced today that Dave deBronkart, ... will deliver the luncheon keynote on Tuesday, May 7, at its 2019 ... empowering partnerships between patients and their medical providers to NCPDP’s Annual Conference, May ...
(Date:2/19/2019)... ... , ... According to a recent study by Columbia University, more than 40% ... and only 26% of widows return to their pre-loss level of life satisfaction, according ... of the most tragic events that one can face. Consequently, many look for a ...
(Date:2/19/2019)... ... February 18, 2019 , ... AdventHealth Connerton is ... Solutions Footwear Sanitizing Stations to maximize infection control for patients and their families. ... as MRSA and C. difficile, which can be transmitted from the bottoms of ...
(Date:2/19/2019)... ... February 19, 2019 , ... ... Create Health, Wealth and Have the Life You Want!” (published by Balboa Press), ... with weight issues to release the pounds, reconnect to their dreams and attain ...
(Date:2/19/2019)... ... February 19, 2019 , ... STAR Institute for ... for occupational therapists beginning March 2019. The focus of the new program is to ... cases. The new Group Supervision Programs will be held on Zoom for five weekly ...
Breaking Medicine News(10 mins):
(Date:2/19/2019)... ... ... ExceleraRx Corporation announced today that St. Luke’s Health System has joined the ... the state of Idaho. , “We are very pleased to welcome St. ... Corp. “We believe St. Luke’s commitment to expanding and leveraging its pharmacy capabilities to ...
(Date:2/19/2019)... ... , ... The Jean Griswold Foundation, a nonprofit named for the founder of ... lives of seniors and others in the communities in which Griswold Home Care operates. ... couldn’t afford them. , “Each of these organizations have made such an ...
(Date:2/19/2019)... , ... February 19, 2019 , ... ... Florida, has completed his new book “Live Hard Die Young.” Dr. Oexner was ... practices chiropractic medicine, therapeutic exercise physiology, and nutritional counseling. Dr. Oexner was a ...
Breaking Medicine Technology:
Cached News: